Robert Teed

Title: Innovations of Robert Teed in Peptide Technology

Introduction

Robert Teed is an accomplished inventor based in Menlo Park, California. He has made significant contributions to the field of peptide technology, particularly in the development of imaging agents for pancreatic tumors. His innovative work has the potential to enhance cancer diagnostics and treatment.

Latest Patents

Robert Teed holds a patent for "Cystine knot peptides that bind alpha-V-beta-6 integrin." This patent discloses peptides that comprise a molecular scaffold portion and a loop portion that binds to integrin αβ. The integrin is expressed on pancreatic tumors, making these peptides useful as imaging agents, among other applications. The peptides demonstrated single-digit nanomolar dissociation constants, comparable to antibodies used clinically for imaging and therapy. They rapidly accumulated in αβ-positive tumors, resulting in excellent tumor-to-normal contrast. Furthermore, the peptides are specific for the targeted integrin αβ receptors expressed on orthotopic pancreatic tumors and various xenografts. Pharmacokinetic-stabilization strategies have endowed these knots with rapid renal clearance, significantly reducing off-target dosing.

Career Highlights

Robert Teed is affiliated with Leland Stanford Junior University, where he continues to advance his research in peptide technology. His work has garnered attention for its potential applications in cancer imaging and therapy.

Collaborations

Teed has collaborated with notable colleagues, including Richard H. Kimura and Sanjiv Sam Gambhir. Their combined expertise has contributed to the success of their research initiatives.

Conclusion

Robert Teed's innovative work in peptide technology represents a significant advancement in the field of cancer diagnostics and treatment. His contributions have the potential to improve patient outcomes and enhance the effectiveness of imaging agents.